Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1996 Sep;224(3):405–417. doi: 10.1097/00000658-199609000-00017

Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir.

L Yang 1, R Hwang 1, L Pandit 1, E M Gordon 1, W F Anderson 1, D Parekh 1
PMCID: PMC1235392  PMID: 8813269

Abstract

OBJECTIVE: The objective of this study was to determine the efficacy of intraperitoneal (IP) injections of a new concentrated herpes simplex thymidine kinase (HS-tk) retroviral vector and ganciclovir (GCV) for peritoneal metastases from pancreas cancer. SUMMARY BACKGROUND DATA: Metastatic pancreas cancer is fatal. Gene therapy may provide a novel approach for this disease. Gene therapy with adeno- or retroviral-mediated transfer of the HS-tk gene into tumor cells renders the cells susceptible to GCV. Intratumoral or intracavity injections of retroviral vectors have been ineffective in previous studies. METHODS: Pancreatic cancer B x PC3 cells (3 x 10(7)) were injected into the tail of pancreas in nude mice. Mice received IP injections of a concentrated HS-tk vector (5 x 10(7)) cfu/mliters) or a control vector (G1Na) without the tk gene for 10 days and GCV (100 mg/kg) for 14 days. To determine whether the vector would survive in the milieu of the peritoneal cavity, the authors examined the effects of ascitic fluid on the vector. Pancreas cancer cells were transduced in vitro with HS-tk vector in presence of media or ascitic fluid and treated with GCV. RESULTS: Highly significant reductions in the mass of metastatic peritoneal tumor deposits were found in HS-tk-treated group (124 +/- 27 mg; n = 11) compared with G1Na vector controls (910 +/- 168 mg; n = 8; p < 0.0001). Results of polymerase chain reaction analysis demonstrated integration of the vector in the tumors, and on immunohistochemistry, expression of the TK protein was seen in the number of surviving colonies (representing nontransduced cells) were similar in both groups, suggesting that the vector effectively transduced tumor cells bathed in the ascitic fluid. CONCLUSIONS: Results demonstrate that IP administration of concentrated retroviral HS-tk vectors is effective treatment for pancreas cancer metastatic to the peritoneal cavity; furthermore, the vector is active in the presence of ascitic fluid. Intraperitoneal retroviral HS-tk may provide a novel approach to treatment of metastatic pancreas cancer.

Full text

PDF
408

Images in this article

410Figure 3.
on p.410
410Figure 4.
on p.410
410Figure 5.
on p.410

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki K., Yoshida T., Sugimura T., Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res. 1995 Sep 1;55(17):3810–3816. [PubMed] [Google Scholar]
  2. Barba D., Hardin J., Sadelain M., Gage F. H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4348–4352. doi: 10.1073/pnas.91.10.4348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chen S. H., Shine H. D., Goodman J. C., Grossman R. G., Woo S. L. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3054–3057. doi: 10.1073/pnas.91.8.3054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cornetta K., Moen R. C., Culver K., Morgan R. A., McLachlin J. R., Sturm S., Selegue J., London W., Blaese R. M., Anderson W. F. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther. 1990 Spring;1(1):15–30. doi: 10.1089/hum.1990.1.1-15. [DOI] [PubMed] [Google Scholar]
  5. Culver K. W., Ram Z., Wallbridge S., Ishii H., Oldfield E. H., Blaese R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992 Jun 12;256(5063):1550–1552. doi: 10.1126/science.1317968. [DOI] [PubMed] [Google Scholar]
  6. Fick J., Barker F. G., 2nd, Dazin P., Westphale E. M., Beyer E. C., Israel M. A. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11071–11075. doi: 10.1073/pnas.92.24.11071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Freeman S. M., Abboud C. N., Whartenby K. A., Packman C. H., Koeplin D. S., Moolten F. L., Abraham G. N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993 Nov 1;53(21):5274–5283. [PubMed] [Google Scholar]
  8. Klapdor R. Perspectives in chemotherapy of pancreatic cancer. Eur J Surg Oncol. 1991 Apr;17(2):153–166. [PubMed] [Google Scholar]
  9. Kotani H., Newton P. B., 3rd, Zhang S., Chiang Y. L., Otto E., Weaver L., Blaese R. M., Anderson W. F., McGarrity G. J. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther. 1994 Jan;5(1):19–28. doi: 10.1089/hum.1994.5.1-19. [DOI] [PubMed] [Google Scholar]
  10. Lampson L. A., Lampson M. A., Dunne A. D. Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ. Cancer Res. 1993 Jan 1;53(1):176–182. [PubMed] [Google Scholar]
  11. Los G., Verdegaal E. M., Mutsaers P. H., McVie J. G. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28(3):159–165. doi: 10.1007/BF00685503. [DOI] [PubMed] [Google Scholar]
  12. Merrick H. W., 3rd, Dobelbower R. R., Jr Aggressive therapy for cancer of the pancreas. Does it help? Gastroenterol Clin North Am. 1990 Dec;19(4):935–962. [PubMed] [Google Scholar]
  13. Moolten F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986 Oct;46(10):5276–5281. [PubMed] [Google Scholar]
  14. Silverberg E., Boring C. C., Squires T. S. Cancer statistics, 1990. CA Cancer J Clin. 1990 Jan-Feb;40(1):9–26. [PubMed] [Google Scholar]
  15. Smythe W. R., Hwang H. C., Elshami A. A., Amin K. M., Albelda S. M., Kaiser L. R. Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. J Thorac Cardiovasc Surg. 1995 Apr;109(4):626–631. doi: 10.1016/S0022-5223(95)70342-X. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES